Professor, Department of Hematology and Medical Oncology​

Roberto C. Goizueta Distinguished Chair for Cancer Research​

Winship Cancer Institute, Emory University School of Medicine​

Atlanta, Georgia, United States


Suresh S. Ramalingam is the Executive Director of the Winship Cancer Institute of Emory University. He serves as Professor of Hematology and Medical Oncology and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine.​​

Dr. Ramalingam’s research is focused on the development of novel treatment approaches for patients with lung cancer. Specifically, his group has developed novel treatment options for lung cancer patients harboring an EGFR mutation, resulting in FDA approval of third generation inhibitors for metastatic NSCLC. He also leads clinical and translational investigations of novel immunotherapy approaches for the treatment of lung cancer. He has published more than 350 original manuscripts, review articles, editorials and book chapters. He serves as the principal investigator for the Emory University Lung Cancer SPORE award from the National Cancer Institute. He is also the contact principal investigator for the ECOG-ACRIN Thoracic Malignancies Translational Science Center Award from the National Cancer Institute.​​

Dr. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee and Deputy Chair for Therapeutics Programs at ECOG-ACRIN. He is the Editor-in-Chief for ‘Cancer’ journal (American Cancer Society). Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI ‘Clinical Investigators Team Leadership Award’ (2010-12). Dr. Ramalingam served as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC)  2017-21) and as a member of the NCI Thoracic Malignancies Steering Committee. He is past president of the Georgia Society of Oncology and a former member of the Emory Healthcare board of directors.​​

Dr. Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, MI, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, PA